EVENTS | VIEW CALENDAR
Adimab partners with Celgene for therapeutic antibodies
LEBANON, N.H.—Adimab, LLC, a company specializing in fully human antibodies, has announced the establishment of a multi-target discovery collaboration with biopharmaceutical company Celgene Corporation. Adimab works with a proprietary, fully human, yeast-based platform.
"We are very pleased to announce another major pharma partnership," Tillman Gerngross, CEO and co-founder of Adimab, said in a press release regarding the agreement. "Celgene has developed a highly successful oncology and inflammation franchise, and we are excited to partner with them to support their expanding antibody-based therapeutic portfolio."
Per the terms of the agreement, Adimab will utilize its proprietary platform for the generation of therapeutic antibodies against multiple targets. For each target, Celgene will have the right to develop and commercialize all therapeutic antibodies that are generated under the collaboration for possible use as therapeutic products. Though no specific financial terms were released, Adimab will receive an undisclosed upfront payment from Celgene. In addition, should Celgene choose to exercise its option for any of the targets, Adimab will be eligible for license fees, clinical milestones and royalties on therapeutic product sales.
Adimab's platform is capable of providing a readout in a matter of hours, compared to the days it takes to generate a readout from human B-cell/hybridoma cell lines.
"The speed and technical superiority of our platform drives all of our deal flow," said Guy Van Meter, vice president of Business Development at Adimab, commented in a statement. "The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization and bispecifics."
Adimab announced another agreement the same day, this one with Innovent Biologics, Inc. The two companies have formed a therapeutic discovery partnership for the discovery, development and commercialization of an antibody-based therapeutic program. Per the terms of the agreement, Adimab will make use of its antibody discovery and optimization platform to identify a fully human therapeutic antibody against a target that Innovent will select. Innovent will be in charge of initial product development, manufacturing and clinical trials, and both companies will retain rights to develop and commercialize the therapeutic program in their respective territories.
In 2013 alone, Adimab has announced the establishment or expansion of agreements with seven companies. The organization inked a discovery collaboration with Kyowa Hakko Kirin and expanded collaborations with Merck and Lilly in January, and announced its first technology transfer agreement with GlaxoSmithKline and its second technology transfer agreement with Biogen Idec in July. Adimab has also established agreements in recent years with Gilead, Novo Nordisk A/S and Genentech.